Pharmacogenomics in Pregnancy and Lactation

Pharmacogenomics in pregnancy and lactation examines how inherited variation in drug response interacts with the profound physiological adaptations of the perinatal period. Pregnancy alters drug absorption, distribution, and especially metabolism — the activity of several cytochrome P450 enzymes changes markedly across gestation — and a second, genetically distinct individual, the fetus, is exposed through the placenta. The field studies how maternal genotype, pregnancy-induced changes in enzyme activity, and fetal exposure jointly shape drug response.

Definition

Pharmacogenomics in pregnancy and lactation is the study of how heritable maternal (and, where relevant, fetal) determinants of drug response interact with the physiological adaptations of pregnancy and lactation to shape drug exposure and effect in the mother and the fetus or breastfed infant.

Scope

The entry covers pregnancy-induced pharmacokinetic change, the interaction of these changes with maternal pharmacogenes, and the conceptual role of the maternal-fetal-placental unit and of transfer into breast milk. Evidence in this population is limited, and the entry treats the subject as a methodological and conceptual topic rather than as dosing or treatment guidance.

Core questions

• How do pregnancy-induced changes in enzyme activity interact with maternal pharmacogenotype to alter drug exposure?
• How does the maternal-fetal-placental unit complicate the genotype-to-phenotype relationship for drug response?
• What governs drug and metabolite transfer across the placenta and into breast milk?
• Why is pharmacogenomic evidence so limited in this population, and what are the consequences for interpretation?

Key concepts

• Pregnancy-induced pharmacokinetic change
• Gestational changes in cytochrome P450 activity
• Maternal-fetal-placental unit
• Placental drug transfer
• Transfer into breast milk
• Evidence scarcity in pregnancy

Mechanisms

Pregnancy changes drug disposition through increased plasma volume and body water, altered protein binding, increased renal clearance, and gestation-dependent shifts in hepatic and intestinal enzyme activity, with some cytochrome P450 enzymes induced and others reduced as pregnancy advances. These physiological changes are superimposed on the mother's germline pharmacogenotype, so the observed drug-response phenotype reflects both inherited enzyme capacity and the pregnancy-modulated expression of those enzymes. Drugs and active metabolites can also cross the placenta to reach the fetus, whose own developing and genetically distinct enzyme systems then act on them, and lipophilic drugs may pass into breast milk during lactation. The combined effect is a maternal-fetal system in which interpreting a single maternal genotype requires accounting for gestational stage, placental transfer, and, after birth, lactational exposure.

Clinical relevance

This topic helps clinicians and trainees understand why pharmacogenomic interpretation in pregnant and lactating patients must account for gestation-dependent physiology and for exposure of the fetus or infant. It is reference-educational, describing how perinatal drug-response evidence is generated and reasoned about, and is not a basis for individual dosing or treatment decisions.

Epidemiology

Pregnant and lactating people carry the general population distribution of pharmacogene variants, but they are systematically under-represented in pharmacological research, so direct pharmacogenomic evidence in pregnancy is sparse relative to other populations.

Evidence & guidelines

Because pregnant and lactating individuals are commonly excluded from trials, pharmacogenomic guidance specific to pregnancy is limited, and recommendations are typically extrapolated from non-pregnant adults while accounting for documented pregnancy-induced changes in enzyme activity. PharmGKB and consortia curate the broader gene-drug evidence base.

History

Clinical pharmacology in pregnancy long emphasised avoidance and caution because of teratogenic risk and limited data. Mechanistic work established that pregnancy systematically alters drug disposition, including enzyme-specific changes in metabolism, and as pharmacogenomics developed it became clear that inherited variation must be interpreted against these gestational changes and against fetal and lactational exposure, defining a distinct but evidence-limited subfield.

Debates

How should pharmacogenomic recommendations be applied when pregnancy data are scarce?

Pregnant and lactating people are largely excluded from pharmacogenomic research, so whether and how to extrapolate non-pregnant gene-drug recommendations to pregnancy, given documented gestational changes in enzyme activity, is an unresolved evidence and ethics problem.

Key figures

• Gail Anderson
• Mary Relling
• William Evans

Seminal works

• anderson-2005
• evans-2003
• relling-2015

Frequently asked questions

Does pregnancy change how a drug-response genotype behaves?

The genotype itself does not change, but pregnancy alters the activity of several drug-metabolizing enzymes across gestation, so the same maternal genotype can translate into different drug exposure at different points in pregnancy.

Why is pharmacogenomic evidence in pregnancy so limited?

Pregnant and lactating people are usually excluded from drug and pharmacogenomic studies for safety reasons, so direct evidence is sparse and guidance is often extrapolated from non-pregnant adults.